SÉMINAIRES ET CONFÉRENCES



RYAN POTTS

Vice-President and Head, Induced Proximity Platform, Amgen Inc.

"Any target, every time: how proximity-based therapeutics has redefined druggability"

Induced proximity is a novel strategy for targeting the highly intractable proteins that are involved in many human diseases. By bringing together disease targets and biological effectors, such as enzymes, ubiquitin ligases, or transcription factors, proximity-based therapeutics can modulate the function, stability, or localization of the target proteins. This approach can overcome some of the limitations of conventional small molecules or biologics, such as poor selectivity, low potency, or unfavorable pharmacokinetics. My talk will cover the difficulties we encounter in finding new drugs and the potential of using proximity biology to address challenging drug targets. I will explain the principles of proximity-based treatments and showcase some examples, such as targeted protein or RNA degradation, as well as molecular glues that stabilize weak, biologically meaningful interactions. I'll show how Amgen's Induced Proximity Platform is using basic biological knowledge of targets and effectors along with adaptable chemistry platforms to progress the new generation of drug discovery programs.

AstraZeneca

Boehringer

Ingelheim





Vendredi 2 août 2024, 11h30 Pavillon André-Aisenstadt, Salle : 1177

ET

LIEN ZOOM

invité de Stephen Michnick stephen.michnick@umontreal.ca